{"result": {"id": "3bc8c071-e514-43d2-a426-ff2b88a7bbe7", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>EURJVASCENDOVACSURG<|>ORGANIZATION<|>A medical journal publishing research on vascular and endovascular surgery\")  \n##  \n(\"entity\"<|>ZHENG Y<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>CAI GY<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>CHEN XM<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>CHIN MED J (ENGL)<|>ORGANIZATION<|>A medical journal publishing research in English\")  \n##  \n(\"entity\"<|>ZHANG W<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>SHI W<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>LIU Z<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>SCI REP<|>ORGANIZATION<|>A scientific journal publishing research reports\")  \n##  \n(\"entity\"<|>TANG L<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>NEPHROL DIAL TRANSPLANT<|>ORGANIZATION<|>A medical journal focusing on nephrology, dialysis, and transplantation\")  \n##  \n(\"entity\"<|>WANG C<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>LI Y<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>ZHANG J<|>PERSON<|>A researcher involved in studies on hypertension and chronic kidney disease\")  \n##  \n(\"entity\"<|>J AM HEART ASSOC<|>ORGANIZATION<|>A journal publishing research on cardiovascular medicine\")  \n##  \n(\"entity\"<|>中国老年医学学会高血压分会<|>ORGANIZATION<|>Chinese Geriatrics Society Hypertension Branch, involved in hypertension management guidelines\")  \n##  \n(\"entity\"<|>国家老年疾病临床医学研究中心中国老年心血管病防治联盟<|>ORGANIZATION<|>National Clinical Research Center for Geriatric Diseases, China Elderly Cardiovascular Disease Prevention and Treatment Alliance\")  \n##  \n(\"entity\"<|>DOUROS A<|>PERSON<|>A researcher involved in studies on blood pressure and mortality in older adults\")  \n##  \n(\"entity\"<|>TÖLLE M<|>PERSON<|>A researcher involved in studies on blood pressure and mortality in older adults\")  \n##  \n(\"entity\"<|>EBERT N<|>PERSON<|>A researcher involved in studies on blood pressure and mortality in older adults\")  \n##  \n(\"entity\"<|>EUR HEART J<|>ORGANIZATION<|>A journal publishing research on cardiovascular medicine\")  \n##  \n(\"entity\"<|>XIE X<|>PERSON<|>A researcher involved in studies on renin-angiotensin system inhibitors\")  \n##  \n(\"entity\"<|>PERKOVIC V<|>PERSON<|>A researcher involved in studies on renin-angiotensin system inhibitors\")  \n##  \n(\"entity\"<|>AM J KIDNEY DIS<|>ORGANIZATION<|>A journal publishing research on kidney diseases\")  \n##  \n(\"entity\"<|>KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO)<|>ORGANIZATION<|>An organization developing clinical practice guidelines for kidney disease management\")  \n##  \n(\"entity\"<|>ITO S<|>PERSON<|>A researcher involved in studies on hypertension and renal dysfunction\")  \n##  \n(\"entity\"<|>SATOH M<|>PERSON<|>A researcher involved in studies on hypertension and renal dysfunction\")  \n##  \n(\"entity\"<|>TAMAKI Y<|>PERSON<|>A researcher involved in studies on hypertension and renal dysfunction\")  \n##  \n(\"entity\"<|>HYPERTENS RES<|>ORGANIZATION<|>A journal publishing research on hypertension\")  \n##  \n(\"entity\"<|>MCAUSLAND FR<|>PERSON<|>A researcher involved in studies on angiotensin-neprilysin inhibition\")  \n##  \n(\"entity\"<|>LEFKOWITZ MP<|>PERSON<|>A researcher involved in studies on angiotensin-neprilysin inhibition\")  \n##  \n(\"entity\"<|>CLAGGETT B<|>PERSON<|>A researcher involved in studies on angiotensin-neprilysin inhibition\")  \n##  \n(\"entity\"<|>EUR J HEART FAIL<|>ORGANIZATION<|>A journal publishing research on heart failure\")  \n##  \n(\"entity\"<|>FLYTHE JE<|>PERSON<|>A researcher involved in studies on blood pressure management in dialysis\")  \n##  \n(\"entity\"<|>CHANG TI<|>PERSON<|>A researcher involved in studies on blood pressure management in dialysis\")  \n##  \n(\"entity\"<|>GALLAGHER MP<|>PERSON<|>A researcher involved in studies on blood pressure management in dialysis\")  \n##  \n(\"entity\"<|>中国医师协会肾脏病医师分会血液透析充分性协作组<|>ORGANIZATION<|>Chinese Medical Doctor Association Nephrology Branch Hemodialysis Adequacy Working Group\")  \n##  \n(\"entity\"<|>WANG AY<|>PERSON<|>A researcher involved in studies on cardiovascular and metabolic guidelines in peritoneal dialysis\")  \n##  \n(\"entity\"<|>BRIMBLE KS<|>PERSON<|>A researcher involved in studies on cardiovascular and metabolic guidelines in peritoneal dialysis\")  \n##  \n(\"entity\"<|>BRUNIER G<|>PERSON<|>A researcher involved in studies on cardiovascular and metabolic guidelines in peritoneal dialysis\")  \n##  \n(\"entity\"<|>PERIT DIAL INT<|>ORGANIZATION<|>A journal publishing research on peritoneal dialysis\")  \n##  \n(\"entity\"<|>DONG J<|>PERSON<|>A researcher involved in studies on volume management in peritoneal dialysis\")  \n##  \n(\"entity\"<|>XU X<|>PERSON<|>A researcher involved in studies on volume management in peritoneal dialysis\")  \n##  \n(\"entity\"<|>ZHANG YQ<|>PERSON<|>A researcher involved in studies on blood pressure control in diabetes mellitus\")  \n##  \n(\"entity\"<|>DONG YG<|>PERSON<|>A researcher involved in studies on blood pressure control in diabetes mellitus\")  \n##  \n(\"entity\"<|>J CLIN HYPERTENS (GREENWICH)<|>ORGANIZATION<|>A journal publishing research on clinical hypertension\")  \n##  \n(\"entity\"<|>DE BOER IH<|>PERSON<|>A researcher involved in studies on diabetes and hypertension\")  \n##  \n(\"entity\"<|>BANGALORE S<|>PERSON<|>A researcher involved in studies on diabetes and hypertension\")  \n##  \n(\"entity\"<|>BENETOS A<|>PERSON<|>A researcher involved in studies on diabetes and hypertension\")  \n##  \n(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>An organization providing guidelines on diabetes and hypertension\")  \n##  \n(\"entity\"<|>DIABETES CARE<|>ORGANIZATION<|>A journal publishing research on diabetes care\")  \n##  \n(\"entity\"<|>EMDIN CA<|>PERSON<|>A researcher involved in studies on diabetes and hypertension\")  \n##  \n(\"entity\"<|>RAHIMI K<|>PERSON<|>A researcher involved in studies on diabetes and hypertension\")  \n##  \n(\"entity\"<|>NEAL B<|>PERSON<|>A researcher involved in studies on diabetes and hypertension\")  \n##  \n(\"relationship\"<|>ZHENG Y<|>CAI GY<|>Co-authors of research on hypertension and chronic kidney disease<|>5\")  \n##  \n(\"relationship\"<|>ZHENG Y<|>CHEN XM<|>Co-authors of research on hypertension and chronic kidney disease<|>5\")  \n##  \n(\"relationship\"<|>ZHANG W<|>SHI W<|>Co-authors of research on hypertension and chronic kidney disease<|>5\")  \n##  \n(\"relationship\"<|>ZHANG W<|>LIU Z<|>Co-authors of research on hypertension and chronic kidney disease<|>5\")  \n##  \n(\"relationship\"<|>WANG C<|>LI Y<|>Co-authors of research on hypertension and chronic kidney disease<|>5\")  \n##  \n(\"relationship\"<|>WANG C<|>ZHANG J<|>Co-authors of research on hypertension and chronic kidney disease<|>5\")  \n##  \n(\"relationship\"<|>DOUROS A<|>TÖLLE M<|>Co-authors of research on blood pressure and mortality in older adults<|>5\")  \n##  \n(\"relationship\"<|>DOUROS A<|>EBERT N<|>Co-authors of research on blood pressure and mortality in older adults<|>5\")  \n##  \n(\"relationship\"<|>XIE X<|>PERKOVIC V<|>Co-authors of research on renin-angiotensin system inhibitors<|>5\")  \n##  \n(\"relationship\"<|>ITO S<|>SATOH M<|>Co-authors of research on hypertension and renal dysfunction<|>5\")  \n##  \n(\"relationship\"<|>ITO S<|>TAMAKI Y<|>Co-authors of research on hypertension and renal dysfunction<|>5\")  \n##  \n(\"relationship\"<|>MCAUSLAND FR<|>LEFKOWITZ MP<|>Co-authors of research on angiotensin-neprilysin inhibition<|>5\")  \n##  \n(\"relationship\"<|>MCAUSLAND FR<|>CLAGGETT B<|>Co-authors of research on angiotensin-neprilysin inhibition<|>5\")  \n##  \n(\"relationship\"<|>FLYTHE JE<|>CHANG TI<|>Co-authors of research on blood pressure management in dialysis<|>5\")  \n##  \n(\"relationship\"<|>FLYTHE JE<|>GALLAGHER MP<|>Co-authors of research on blood pressure management in dialysis<|>5\")  \n##  \n(\"relationship\"<|>WANG AY<|>BRIMBLE KS<|>Co-authors of research on cardiovascular and metabolic guidelines in peritoneal dialysis<|>5\")  \n##  \n(\"relationship\"<|>WANG AY<|>BRUNIER G<|>Co-authors of research on cardiovascular and metabolic guidelines in peritoneal dialysis<|>5\")  \n##  \n(\"relationship\"<|>ZHANG YQ<|>DONG YG<|>Co-authors of research on blood pressure control in diabetes mellitus<|>5\")  \n##  \n(\"relationship\"<|>DE BOER IH<|>BANGALORE S<|>Co-authors of research on diabetes and hypertension<|>5\")  \n##  \n(\"relationship\"<|>DE BOER IH<|>BENETOS A<|>Co-authors of research on diabetes and hypertension<|>5\")  \n##  \n(\"relationship\"<|>EMDIN CA<|>RAHIMI K<|>Co-authors of research on diabetes and hypertension<|>5\")  \n##  \n(\"relationship\"<|>EMDIN CA<|>NEAL B<|>Co-authors of research on diabetes and hypertension<|>5\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559034, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 2687, "prompt_tokens": 2865, "total_tokens": 5552, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1073}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ]. EurJVascEndovascSurg,2009,37(4Suppl) :1-19.\n[585]  Zheng Y, CaiGY,  Chen XM, et al.  Prevalence, awareness,  treatment, andcontrolofhypertensioninthenon-dialysischron- ickidney disease patients[J]. Chin MedJ (Engl) , 2013, 126\n(12) :2276-2280.\n[586]  Zhang W , ShiW , Liu Z, et al.  A nationwide cross-sectional survey on prevalence, management and pharmacoepidemiology patternson hypertensioninChinesepatientswith chronickidney disease[J]. SciRep,2016,6:38768.\n[587]  ZhengY, TangL, ZhangW , etal. Applyingthenew intensive blood pressurecategoriesto anondialysis chronickidneydisease population: the prevalence,  awareness and treatment rates in chronickidney disease patients with hypertension in China sur- vey[J]. NephrolDialTransplant,2020,35(1) :155-161.\n[588]  WangC, LiY, ZhangJ, etal. Prognosticeffectofisolatednoc- turnalhypertension in Chinese patients with nondialysis chronic kidneydisease[J]. JAm HeartAssoc,2016,5(10) :e004198.\n[589]  中国老年医学学会高血压分会 , 国家老年疾病临床医学研究中  心中国老年心血管病防治联盟.  中国老年高血压管理指南 2019 [J]. 中华高血压杂志 ,2019,27(2) :111-135.\n[590]  DourosA, T?lleM, EbertN, etal.  Controlofblood pressure and riskofmortalityinacohortofolderadults: theBerlinInitia- tiveStudy[J]. EurHeartJ,2019,40(25) :2021-2028.\n[591]  XieX, Liu Y, PerkovicV, etal. Renin-angiotensin system in- hibitorsand kidneyand cardiovascularoutcomesinpatientswith CKD: a Bayesian network meta-analysis of randomized clinical trials[J]. Am J KidneyDis,2016,67(5) :728-741.\n[592]  Kidney Disease:  Improving Global Outcomes (KDIGO)  Blood PressureWork Group.  KDIGO 2021 clinical practice guideline forthemanagementofblood pressure in chronic kidney disease [J]. KidneyInt,2021,99(3S) :S1-S87.\n[593]  ItoS, SatohM, TamakiY, etal. SafetyandefficacyofLCZ696, a first-in-class angiotensin receptor neprilysin inhibitor,  in Japa- nesepatients with hypertension and renal dysfunction[J]. Hy- pertensRes,2015,38(4) :269-275.\n\n\n[594]  McCausland FR, Lefkowitz MP, ClaggettB, etal.  Angioten- sin-neprilysin inhibition and renaloutcomes across the spectrum  ofejection fractionin heartfailure[J]. EurJ HeartFail,2022,24\n(9) :1591-1598.\n[595]  FlytheJE, ChangTI, GallagherMP, etal. Blood pressureand volumemanagementin dialysis: conclusionsfrom aKidneyDis- ease: ImprovingGlobalOutcomes(KDIGO) ControversiesCon- ference[J]. KidneyInt,2020,97(5) :861-876.\n[596]  中国医师协会肾脏病医师分会血液透析充分性协作组.  中国血 液透析充分性临床实践指南[J]. 中华医学杂志 , 2015, 95(34) : 2748-2753.\n[597]  WangAY, BrimbleKS, BrunierG, etal.  ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients.   Part Ⅰ-assessment and management of various cardiovascular risk factors[J]. PeritDialInt,2015,35(4) :379-387.\n[598]  WangAY, DongJ, Xu X, etal.  Volumemanagementasakey dimension ofa high-quality PD prescription[J]. PeritDial Int,  2020,40(3) :282-292.\n[599]  ZhangYQ, LiY, DongYG, etal. A nationwideassessmentof blood pressurecontroland theassociatedfactorsin Chinesetype 2 diabetesmellituspatients[J]. J Clin Hypertens(Greenwich) ,  2019,21(11) :1654-1663.\n[600]  deBoerIH, BangaloreS, BenetosA, etal. Diabetesandhyper- tension: aposition statementbytheAmericanDiabetesAssocia- tion[J]. DiabetesCare,2017,40(9) :1273-1284.\n[601]  EmdinCA, RahimiK, NealB, etal\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_2a0de442ac46f5ae9fba70266d0c3fd1eadee28423330e2d04d25e1470a0ef36_v2"}